Litigation Details for Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG (S.D.N.Y. 2020)
✉ Email this page to a colleague
Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG (S.D.N.Y. 2020)
| Docket | ⤷ Sign Up | Date Filed | 2020-07-17 |
| Court | District Court, S.D. New York | Date Terminated | 2021-09-21 |
| Cause | 15:1 Antitrust Litigation (Monopolizing Trade) | Assigned To | Alison Julie Nathan |
| Jury Demand | Plaintiff | Referred To | |
| Patents | 9,220,631 | ||
| Link to Docket | External link to docket | ||
Details for Regeneron Pharmaceuticals Inc. v. Novartis Pharma AG (S.D.N.Y. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 0000-00-00 | External link to document | |||
| 2020-07-17 | 1 | Complaint | succeeded in obtaining a patent—U.S. Patent No. 9,220,631 (the “’631 Patent”)—broadly claiming a PFS …of the ’631 Patent) showing that the claimed PFS in Novartis’s patent was not patentable. Separately,…the patentability of claims of the ’631 Patent. As detailed below, the claims of the ’631 Patent would…material to the patentability of the claims of the ’631 Patent because the ’631 Patent would not have …PFS, Novartis could secure its patent only by ensuring that the U.S. Patent and Trademark Office (“USPTO | External link to document |
| 2021-03-02 | 103 | Protective Order | (a) “’631 Patent” refers to United States Patent No. 9,220,631. (b) …foreign patents or patent applications, or any other domestic or foreign patent or patent application… or foreign patent or patent application claiming priority to the ’631 Patent or any related… or foreign patent or patent application claiming priority to the ’631 Patent or any related…modifying of patent claims or participation in domestic and/or foreign patent office correspondence | External link to document |
| 2021-04-12 | 112 | Exhibit A - ITC Staff Brief | of certain claims of U.S. Patent No. 9,220,631 (JX-0001) (“the ’631 patent”) based on the importation….................... 21 IV. U.S. PATENT NO. 9,220,631 ........................................… Public Version IV. U.S. PATENT NO. 9,220,631 A. Claim Construction …syringe. (Id.) D. The ’631 Patent The ’631 patent is titled “SYRINGE” and issued on December…, selling, or importing a patented invention without consent of the patent owner. 35 U.S.C. § 271(a). | External link to document |
| 2021-09-21 | 139 | Memorandum & Opinion | of the underlying patent application for U.S. Patent No. 9,220,631 (the ‘631 Patent). Id. ¶¶ 8, 256. …the ‘631 Patent “through fraud on the USPTO.” Id. Regeneron alleges that the ‘631 Patent dramatically…Novartis’s patent infringement suit. As outlined above, the enforceability of the ‘631 Patent runs throughout…. The ‘631 Patent “broadly claim[s] a PFS with any anti-VEGF, including EYELEA.” Id. ¶ 8. According to… to Regeneron, the ‘631 Patent is at “the heart of Defendants’ anticompetitive conduct” and a “cornerstone | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
